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with an efficacious oral drug could reduce these figures to
800 GBP per avoided case. In the US, preemptive therapy
with IV ganciclovir is currently a dominant strategy com-
pared with a "wait and treat" option with IV ganciclovir
($500 less expensive and avoids 18 CMV cases per 100).
This reflects the trend to provide preemptive therapy in
ambulatory settings. There is potential for new oral pro-
phylactic therapies, of similar efficacy to existing thera-
pies, that could result in further cost savings.
CONCLUSIONS: The model demonstrates the cost-
effectiveness of preemptive therapy in ambulatory set-
tings compared with inpatient treatment of CMV disease
(US), suggesting a potential cost-effectiveness of new oral
prophylactic therapies.
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AmoxicillinlClavulanic acid, Cefotaxime, Ceftriaxone,
and TazobactamlPiperacillin are some of the most pre-
ferred antibiotics to treat skin and soft tissue infection. In
a retrospective analysis, the cost structure was established.
OBJECTIVE: The purpose of this study was to analyze
the medical and economic relevance of above alternative
antibiotic treatments based on multicenter clinical stud-
ies. The comparison of costs and benefits was made on
the basis of a cost-effectiveness analysis.
METHODS: A one-patient model was considered first. In
the one-patient model (Markov model) three states were
constructed: (1) successful therapy, (2) failed therapy be-
cause of ADRs, (3) failed therapy because of lack of efficacy.
Health care costs included in the model were all medical
costs (hospitalization, drug costs, etc.) and indirect costs (ab-
sence from workplace). Indirect costs are calculated with the
human capital approach. Success was defined as the clinical
curing and improvement rate. The success rates were
95% (TazobactamlPiperacillin), 94% (AmoxicillinlClavu-
lanic acid), 90% (Cefotaxime), and 98% (Ceftriaxone).
RESULTS: Therapy with TazobactamlPiperaciliin resulted
in a total cost of DM 3,638 per successfully treated patient.
Therapy with AmoxicillinlClavulanic acid caused total
costs of DM 3,355, therapy with Ceftriaxone caused to-
tal costs of DM 4,221 and therapy with Cefotaxime DM
6,474. Sensitivity analyses were performed to prove the
stability of the results.
CONCLUSION: This cost-effectiveness analysis reveals
that a combination therapy with TazobactamlPiperacillin
incurs lower total costs per successfully treated patient
than Ceftriaxone and Cefotaxime. AmoxicillinlClavu-
lanic acid is the treatment with the lowest costs per suc-
cessfully treated patient.
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Kaposi sarcoma (KS) prior to 1980 was a rare indolent
disorder seen in elderly men of Eastern European descent.
Today it is the most common neoplasm seen in patients
with AIDS and has been estimated to contribute to 25%
of the deaths. Chemotherapy is the mainstay treatment of
KS in patients with extensive or progressive disease in-
volving the visceral organs and lymph nodes. Two agents,
liposomal daunorubicin (Daunoxornev) and liposomal
doxorubicin (Doxil"), have replaced treatment with the
toxic combination of ABV.
OBJECTIVE: Develop a decision analysis model compar-
ing the cost-effectiveness of Daunoxome and Doxil in se-
vere KS.
METHODS: Probabilities used to determine patient re-
sponses and complication rates were obtained from clini-
cal trials and data reflecting our KS population. The
model assumed treatment of severe KS (CD4 (150) pa-
tients not previously treated with chemotherapy. It includes
direct cost associated with drug acquisition, physician mon-
itoring, administration of product, drug administration
cost, and treatment of complications. Probabilities and
direct cost data for nausea and vomiting, peripheral neur-
opathy, neutropenia, alopecia, and serious opportunistic
infections were included in the model. Drug cost reflects
dosing regimens currently in use: Daunoxom, 40 mg/m2
every 2 weeks, or Doxil, 20 mg/m2 every 2 weeks for six
cycles. Effectiveness was determined using the median du-
ration of response to therapy reported in clinical trials.
RESULTS: The cost effectiveness ratio for Daunoxome is
$24,263/median remission year versus $32,767 for
Doxil. One-way sensitivity analysis did not substantially
alter the results. The model also demonstrates Daunox-
orne to have a marginal cost advantage of $2,176
(20.9%) over Doxil.
CONCLUSION: The model identifies Daunoxome as the
most cost-effective and least expensive agent in the treat-
ment ofKS.
